Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Axios on your phone

Get breaking news and scoops on the go with the Axios app.

Download for free.

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Photo: Lev Radin/Pacific Press/LightRocket via Getty Images

The Food and Drug Administration has approved a lower dose of Regeneron’s coronavirus treatment for injection, the company announced Friday.

Why it matters: The update to the company's emergency use authorization, which was first issued in November, will make it easier for doctors to administer the treatment to coronavirus patients, since they can now do so by simple injection rather than intravenous infusion.

The big picture: Health officials have said Regeneron’s monoclonal antibodies drug has been underused partly because not all clinics and hospitals are equipped to administer intravenous infusions, according to the Wall Street Journal.

What they're saying: "Despite increased use of vaccines, thousands of patients are still becoming infected in the U.S. every day, with many at high risk of serious complications from COVID-19," George D. Yancopoulos, president and chief scientific officer at Regeneron, said in a statement.

  • "Unfortunately, to date only a fraction of patients eligible for antibody treatments have received them, which we hope will change based on this updated FDA authorization."

Go deeper: Why coronavirus patients aren't getting a promising treatment

Go deeper

Jun 3, 2021 - World

2 billion global vaccinations: Where the doses have gone

Expand chart
Data: Our World in Data; Chart: Danielle Alberti/Axios

The world reached a vaccination milestone this week, with 2 billion total doses now administered, according to the tracker from Our World in Data.

Why it matters: The global rate is speeding up considerably. It took 30 days to go from 500 million doses to 1 billion, 24 days to go from 1 billion to 1.5 billion, and just 16 days to jump from 1.5 billion to 2 billion.

Jun 3, 2021 - Health

Prepping for the next big outbreak

Illustration: Eniola Odetunde/Axios

Scientists and public health experts are trying to leverage lessons from the COVID-19 pandemic to spur the development of technologies and infrastructure needed to stop the next big outbreak.

Why it matters: Scientists predict infectious disease outbreaks will become more frequent, and the COVID-19 pandemic showed the enormous costs of not being adequately prepared.

Jun 4, 2021 - Health

FDA faces critical test with Alzheimer's drug decision

Illustration: Aïda Amer/Axios

The FDA will soon decide the fate of Biogen's experimental Alzheimer's drug. But there is one glaring issue — there is no conclusive evidence the drug effectively treats the crippling neurological disease.

Why it matters: This will be one of the FDA's most important decisions in years. The outcome will show whether the federal agency sides with the overwhelming scientific consensus that the drug isn't proven to work, or with an industry and a patient population desperate for anything to be approved.